| Autor: |
Schreuder, Tim C. M. A., Gelderblom, Huub C., Weegink, Christine J., Hamann, Dörte, Reesink, Henk W., DeVries, J. Hans, Hoekstra, Joost B. L., Jansen, Peter L. M. |
| Přispěvatelé: |
Medical Microbiology and Infection Prevention, Gastroenterology and Hepatology, Landsteiner Laboratory, Amsterdam Gastroenterology Endocrinology Metabolism, Endocrinology, Amsterdam Cardiovascular Sciences, General Internal Medicine |
| Jazyk: |
angličtina |
| Rok vydání: |
2008 |
| Zdroj: |
Liver international, 28(1), 39-46. Wiley-Blackwell |
| ISSN: |
1478-3223 |
| Popis: |
BACKGROUND: Development of diabetes mellitus (DM) during or shortly after treatment with interferon alpha (IFN-alpha) in patients with chronic hepatitis C virus (HCV) infection has been reported sporadically. We prospectively screened for DM during and after IFN-alpha therapy for chronic HCV infection. METHODS: Blood glucose levels of patients with chronic HCV infection were routinely assessed at all outpatient visits during and after treatment with pegylated-IFN-alpha (Peg-IFN-alpha) and ribavirin (Riba). RESULTS: Between December 2002 and October 2005, 189 non-diabetic patients were treated with Peg-IFN-alpha/Riba, of whom five developed type 1 DM (2.6%), three type 2 DM (1.6%) and one an indeterminate type of DM. Classical symptoms of DM were present in three patients who developed DM shortly after cessation of Peg-IFN-alpha/Riba. In the other patients, symptoms of DM were either indistinguishable from side effects caused by Peg-IFN-alpha/Riba or absent. CONCLUSION: Our study showed a high incidence of type 1 DM during Peg-IFN-alpha/Riba therapy for chronic HCV infection. Symptoms of DM may be absent or mistaken for Peg-IFN-alpha/Riba-associated side effects. To diagnose DM without delay, we propose routine assessment of blood glucose at all outpatient visits during and after Peg-IFN-alpha/Riba treatment in chronic HCV patients |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text